Skip to content
value.today

ONL Therapeutics, Inc.

Total raised
$109 M
7 rounds on record
Latest round
$60 M
Sep 2024
First round on record
May 2017
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ONL Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2024$60 MNo. 7$50 to $250 million

ONL Therapeutics, Inc.: Raise no. 7, Sep 2024

Investors in this round

35 investors had bought by the notice of Sep 16, 2024: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$60 M of $65 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Constance Chang · Executive Officer
  • David Esposito · Executive Officer, Director
  • David Zacks · Executive Officer
  • Aaron Fletcher · Director
  • Bill Burns · Director
  • Marian Nakada · Director
  • Michal Silverberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Sep 16, 2024. Read the notice at the SEC.

equitySEC
Feb 2024$10 MNo. 6$10 to $50 million

ONL Therapeutics, Inc.: Raise no. 6, Feb 2024

Investors in this round

35 investors had bought by the notice of Mar 12, 2024: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Constance Chang · Executive Officer
  • David Esposito · Executive Officer, Director
  • David Zacks · Executive Officer, Director
  • Bill Burns · Director
  • Mark Hooper · Director
  • Stella Robertson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Mar 12, 2024. Read the notice at the SEC.

equitySEC
Mar 2023$5 MNo. 5$2 to $10 million

ONL Therapeutics, Inc.: Raise no. 5, Mar 2023

Investors in this round

30 investors had bought by the notice of Mar 15, 2023: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $15 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Constance Chang · Executive Officer
  • David Esposito · Executive Officer, Director
  • David Zacks · Executive Officer, Director
  • Bill Burns · Director
  • Mark Hooper · Director
  • Stella Robertson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Mar 15, 2023. Read the notice at the SEC.

equitySEC
Dec 2020$27 MNo. 4$10 to $50 million

ONL Therapeutics, Inc.: Raise no. 4, Dec 2020

Investors in this round

44 investors had bought by the notice of Dec 30, 2020: 44 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $47 M offered; $21 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Esposito · Executive Officer, Director
  • David Zacks · Executive Officer, Director
  • Bill Burns · Director
  • Mark Hooper · Director
  • Stella Robertson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Dec 30, 2020. Read the notice at the SEC.

equitySEC
Oct 2020$2 MNo. 3$2 to $10 million

ONL Therapeutics, Inc.: Raise no. 3, Oct 2020

Investors in this round

3 investors had bought by the notice of Oct 30, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Esposito · Executive Officer, Director
  • David Zacks · Executive Officer, Director
  • Christine Gibbons · Director
  • Felicia David-Visser · Director
  • Mark Hooper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Oct 30, 2020. Read the notice at the SEC.

optionsSEC
Aug 2019$3 MNo. 2$2 to $10 million

ONL Therapeutics, Inc.: Raise no. 2, Aug 2019

Investors in this round

25 investors had bought by the notice of Aug 22, 2019: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Esposito · Executive Officer, Director
  • David Zacks · Executive Officer, Director
  • Christine Gibbons · Director
  • Felicia David-Visser · Director
  • Mark Hooper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Aug 22, 2019. Read the notice at the SEC.

debt, optionsSEC
May 2017$3 MNo. 1$2 to $10 million

ONL Therapeutics, Inc.: Raise no. 1, May 2017

Investors in this round

19 investors had bought by the notice of May 19, 2017: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Zacks · Executive Officer, Director
  • John Freshley · Executive Officer, Director
  • Christine Gibbons · Director
  • Mark Hooper · Director
  • Rafael Castilla · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John K. Freshley, President and CEO. Source: SEC Form D, newest notice filed May 19, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ONL Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2024).

    SEC Form D · Sep 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2024

That is all the official record says: ONL Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of ONL Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 44 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ONL Therapeutics, Inc.
NameRoleNamed in
Constance ChangExecutive officerSep 2024
David EspositoExecutive officerSep 2024
David ZacksExecutive officerSep 2024
John FreshleyExecutive officerMay 2017
Aaron FletcherDirectorSep 2024
Bill BurnsDirectorSep 2024
David EspositoDirectorSep 2024
Marian NakadaDirectorSep 2024
Michal SilverbergDirectorSep 2024
David ZacksDirectorMar 2024
Mark HooperDirectorMar 2024
Stella RobertsonDirectorMar 2024
Christine GibbonsDirectorOct 2020
Felicia David-VisserDirectorOct 2020
John FreshleyDirectorMay 2017
Rafael CastillaDirectorMay 2017